A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bi... by Pavel, M, Schuppan, D, Jost, L, Kerr, D, Harris, A, Jalava, T, Masson, E, Palacay-Radona, M, Koehne, C